{"id":26676,"date":"2025-02-19T10:55:35","date_gmt":"2025-02-19T09:55:35","guid":{"rendered":"https:\/\/www.unither-pharma.com\/finalisation-de-la-cession-de-lactivite-carragelose\/"},"modified":"2026-03-30T17:57:07","modified_gmt":"2026-03-30T15:57:07","slug":"finalisation-de-la-cession-de-lactivite-carragelose","status":"publish","type":"post","link":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/","title":{"rendered":"Finalisation de la cession de l&rsquo;activit\u00e9 Carragelose"},"content":{"rendered":"<h3 data-start=\"38\" data-end=\"153\">Marinomed Biotech AG : Finalisation r\u00e9ussie de la cession de l&rsquo;activit\u00e9 Carragelose \u00e0 Unither Pharmaceuticals<\/h3>\n<ul data-start=\"155\" data-end=\"481\">\n<li data-start=\"155\" data-end=\"328\">Toutes les conditions n\u00e9cessaires \u00e0 la cl\u00f4ture de la transaction, y compris l&rsquo;approbation des actionnaires et la fin de la proc\u00e9dure de restructuration, ont \u00e9t\u00e9 remplies<\/li>\n<li data-start=\"329\" data-end=\"400\">La cl\u00f4ture est assortie d\u2019un paiement initial de 5 millions d\u2019euros<\/li>\n<li data-start=\"401\" data-end=\"481\">Marinomed et Unither ont \u00e9galement conclu un accord de services transitoires<\/li>\n<\/ul>\n<p data-start=\"483\" data-end=\"1122\"><strong data-start=\"483\" data-end=\"524\">Korneuburg, Autriche, 28 f\u00e9vrier 2025<\/strong> \u2013 Marinomed Biotech AG (VSE:MARI) annonce la finalisation r\u00e9ussie de la cession de son activit\u00e9 Carragelose au CDMO (Contract Development and Manufacturing Organization) fran\u00e7ais, Unither Pharmaceuticals. Toutes les conditions n\u00e9cessaires \u00e0 la r\u00e9alisation de la transaction ont \u00e9t\u00e9 remplies : le 19 d\u00e9cembre 2024, les actionnaires de Marinomed ont donn\u00e9 leur approbation lors d\u2019une assembl\u00e9e g\u00e9n\u00e9rale extraordinaire. Le 14 janvier 2025, la proc\u00e9dure de restructuration a \u00e9t\u00e9 officiellement cl\u00f4tur\u00e9e. Enfin, la transaction a \u00e9t\u00e9 valid\u00e9e apr\u00e8s l\u2019examen des investissements \u00e9trangers directs (FDI).<\/p>\n<p data-start=\"1124\" data-end=\"1799\">Le contrat pr\u00e9voit un montant total pouvant atteindre 20 millions d\u2019euros, comprenant un paiement initial de 5 millions d\u2019euros vers\u00e9 \u00e0 la cl\u00f4ture de l\u2019op\u00e9ration. Des paiements suppl\u00e9mentaires seront effectu\u00e9s en fonction de l\u2019atteinte d\u2019objectifs commerciaux et op\u00e9rationnels d\u00e9finis sur les deux prochaines ann\u00e9es. L\u2019accord couvre le transfert de l\u2019int\u00e9gralit\u00e9 du portefeuille Carragelose, incluant tous les contrats et relations commerciales associ\u00e9s. En outre, Marinomed et Unither ont conclu un accord de services transitoires, qui porte sur des prestations dans les domaines des affaires r\u00e9glementaires, du d\u00e9veloppement commercial et de la recherche &amp; d\u00e9veloppement.<\/p>\n<p data-start=\"1801\" data-end=\"2451\"><strong data-start=\"1801\" data-end=\"2130\">\u00ab La cession de l\u2019activit\u00e9 Carragelose \u00e0 Unither Pharmaceuticals constitue une \u00e9tape cl\u00e9. Les fonds issus de cette transaction, y compris le paiement initial de 5 millions d\u2019euros, contribueront au d\u00e9veloppement de nos actifs Marinosolv ainsi qu\u2019\u00e0 la mise en \u0153uvre du plan de restructuration sur les deux prochaines ann\u00e9es \u00bb,<\/strong> d\u00e9clare Andreas Grassauer, PDG de Marinomed. <strong data-start=\"2176\" data-end=\"2449\">\u00ab Nous sommes ravis de collaborer avec Unither pour poursuivre le d\u00e9veloppement du portefeuille Carragelose. Parall\u00e8lement, notre priorit\u00e9 reste la commercialisation de nos actifs Marinosolv, Budesolv et Tacrosolv, ainsi que le d\u00e9veloppement de notre division Solv4U. \u00bb<\/strong><\/p>\n<p data-start=\"2453\" data-end=\"3032\"><strong data-start=\"2453\" data-end=\"2577\">\u00ab L&rsquo;acquisition du portefeuille de produits Carragelose s\u2019inscrit naturellement dans notre r\u00f4le de CDMO international \u00bb,<\/strong> commente <strong data-start=\"2587\" data-end=\"2633\">Eric Goupil, PDG d\u2019Unither Pharmaceuticals<\/strong>. <strong data-start=\"2635\" data-end=\"3030\">\u00ab Cet investissement strat\u00e9gique renforce non seulement notre engagement en faveur de solutions de sant\u00e9 innovantes, mais ouvre \u00e9galement de nouvelles opportunit\u00e9s dans les domaines de la sant\u00e9 respiratoire, des allergies et de l\u2019ophtalmologie. En int\u00e9grant Carragelose \u00e0 notre offre, nous visons \u00e0 proposer des solutions \u00e0 forte valeur ajout\u00e9e, au b\u00e9n\u00e9fice des patients et de nos clients. \u00bb<\/strong><\/p>\n<h3 data-start=\"3039\" data-end=\"3079\"><\/h3>\n<h3 data-start=\"3039\" data-end=\"3079\">\u00c0 propos d\u2019Unither Pharmaceuticals<\/h3>\n<p data-start=\"3081\" data-end=\"3657\">Unither Pharmaceuticals est un sous-traitant pharmaceutique sp\u00e9cialis\u00e9 dans le d\u00e9veloppement et la fabrication de formulations liquides en unidoses et multidoses (notamment des collyres, des solutions salines, des m\u00e9dicaments pour l\u2019asthme en unidoses BFS et des sticks oraux) pour les laboratoires pharmaceutiques innovants et fabricants de g\u00e9n\u00e9riques. Avec 2 305 employ\u00e9s et huit sites de production en France, aux \u00c9tats-Unis, au Br\u00e9sil et en Chine, ainsi qu\u2019un centre R&amp;D en France, Unither Pharmaceuticals a r\u00e9alis\u00e9 un chiffre d\u2019affaires de 522 millions d\u2019euros en 2024.<\/p>\n<p data-start=\"3659\" data-end=\"3683\"><a href=\"http:\/\/www.unither-pharma.com\" target=\"_new\" rel=\"noopener\" data-start=\"3659\" data-end=\"3681\">www.unither-pharma.com<\/a><\/p>\n<h3 data-start=\"3690\" data-end=\"3720\">\u00c0 propos de Carragelose\u00ae<\/h3>\n<p data-start=\"3722\" data-end=\"4284\">Carragelose\u00ae est un polym\u00e8re sulfat\u00e9 extrait d\u2019algues rouges, dot\u00e9 de propri\u00e9t\u00e9s uniques de blocage des virus et des allerg\u00e8nes. Il est reconnu comme une solution douce, efficace et s\u00fbre pour la pr\u00e9vention et le traitement des infections virales respiratoires. Plusieurs \u00e9tudes cliniques et pr\u00e9cliniques ont d\u00e9montr\u00e9 que Carragelose\u00ae forme une barri\u00e8re protectrice sur les muqueuses, emp\u00eachant les virus d\u2019infecter les cellules. Des donn\u00e9es en laboratoire et des essais cliniques ont \u00e9galement r\u00e9v\u00e9l\u00e9 que Carragelose\u00ae peut inhiber la propagation du SARS-CoV-2.<\/p>\n<p data-start=\"4286\" data-end=\"4447\">Les produits Carragelose\u00ae sont commercialis\u00e9s sous licence en Europe, Am\u00e9rique du Nord, Australie ainsi que dans certaines r\u00e9gions d\u2019Asie et d\u2019Am\u00e9rique latine.<\/p>\n<p data-start=\"4449\" data-end=\"4608\">Portefeuille de produits Carragelose\u00ae : <a href=\"http:\/\/www.carragelose.com\/en\/portfolio\/launched-products\" target=\"_new\" rel=\"noopener\" data-start=\"4489\" data-end=\"4539\">www.carragelose.com\/en\/portfolio\/launched-products<\/a><br data-start=\"4539\" data-end=\"4542\" \/>Publications scientifiques : <a href=\"http:\/\/www.carragelose.com\/en\/publications\" target=\"_new\" rel=\"noopener\" data-start=\"4571\" data-end=\"4606\">www.carragelose.com\/en\/publications<\/a><\/p>\n<h3 data-start=\"4615\" data-end=\"4653\">\u00c0 propos de Marinomed Biotech AG<\/h3>\n<p data-start=\"4655\" data-end=\"5056\">Marinomed Biotech AG est une entreprise autrichienne de biotechnologie sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de produits innovants prot\u00e9g\u00e9s par brevet et bas\u00e9s sur sa plateforme Marinosolv\u00ae. Cette technologie permet d\u2019am\u00e9liorer la solubilit\u00e9 et la biodisponibilit\u00e9 des compos\u00e9s faiblement solubles, et est utilis\u00e9e pour d\u00e9velopper de nouveaux traitements ciblant des troubles immunitaires auto-r\u00e9actifs.<\/p>\n<p data-start=\"5058\" data-end=\"5173\">Marinomed Biotech AG est cot\u00e9e \u00e0 la Bourse de Vienne (VSE:MARI) et son si\u00e8ge est situ\u00e9 \u00e0 Korneuburg, en Autriche.<\/p>\n<p data-start=\"5175\" data-end=\"5194\"><a href=\"http:\/\/www.marinomed.com\" target=\"_new\" rel=\"noopener\" data-start=\"5175\" data-end=\"5192\">www.marinomed.com<\/a><\/p>\n<h3 data-start=\"5201\" data-end=\"5238\">Contact presse et investisseurs<\/h3>\n<p data-start=\"5240\" data-end=\"5363\">Marinomed Biotech AG<br data-start=\"5260\" data-end=\"5263\" \/>PR &amp; IR : Lucia Ziegler<br data-start=\"5286\" data-end=\"5289\" \/>T\u00e9l. : +43 2262 90300 158<br data-start=\"5314\" data-end=\"5317\" \/>E-mail : <a rel=\"noopener\" data-start=\"5326\" data-end=\"5342\">pr@marinomed.com<\/a> \/ <a rel=\"noopener\" data-start=\"5345\" data-end=\"5361\">ir@marinomed.com<\/a><\/p>\n<p data-start=\"5240\" data-end=\"5363\"><strong>Avertissement<\/strong><\/p>\n<p data-start=\"5391\" data-end=\"5933\">Ce communiqu\u00e9 contient des d\u00e9clarations prospectives bas\u00e9es sur les perspectives, attentes et projections actuelles de la direction de Marinomed Biotech AG concernant des \u00e9v\u00e9nements futurs. Ces d\u00e9clarations sont soumises \u00e0 des risques, incertitudes et hypoth\u00e8ses susceptibles d&rsquo;entra\u00eener des \u00e9carts significatifs entre les r\u00e9sultats r\u00e9els et ceux d\u00e9crits ou sous-entendus. Les perspectives actuelles peuvent \u00eatre identifi\u00e9es par des expressions telles que \u00ab anticiper \u00bb, \u00ab croire \u00bb, \u00ab estimer \u00bb, \u00ab s\u2019attendre \u00e0 \u00bb, \u00ab pr\u00e9voir \u00bb, \u00ab projeter \u00bb.<\/p>\n<p data-start=\"5935\" data-end=\"6144\">Les d\u00e9clarations prospectives sont valables uniquement \u00e0 la date de publication et Marinomed Biotech AG ne s\u2019engage aucunement \u00e0 les mettre \u00e0 jour en raison de nouvelles informations ou d\u2019\u00e9volutions futures.<\/p>\n<p data-start=\"6146\" data-end=\"6294\">Marinomed et Marinosolv\u00ae sont des marques d\u00e9pos\u00e9es de Marinomed Biotech AG, pouvant \u00eatre d\u00e9tenues ou licenci\u00e9es dans certaines r\u00e9gions uniquement.<\/p>\n<p data-start=\"6296\" data-end=\"6307\">Sources :<\/p>\n<ol data-start=\"6308\" data-end=\"6593\">\n<li data-start=\"6308\" data-end=\"6437\"><a href=\"http:\/\/www.dovepress.com\/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM\" target=\"_new\" rel=\"noopener\" data-start=\"6311\" data-end=\"6435\">www.dovepress.com\/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM<\/a><\/li>\n<li data-start=\"6438\" data-end=\"6593\"><a href=\"http:\/\/www.marinomed.com\/en\/news\/marinomed-biotech-ag-shares-positive-clinical-trial-results-for-iota-carrageenan-nasal-spray-in-the-prevention-of-covid-19-1\" target=\"_new\" rel=\"noopener\" data-start=\"6441\" data-end=\"6591\">www.marinomed.com\/en\/news\/marinomed-biotech-ag-shares-positive-clinical-trial-results-for-iota-carrageenan-nasal-spray-in-the-prevention-of-covid-19-1<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Marinomed Biotech AG : Finalisation r\u00e9ussie de la cession de l&rsquo;activit\u00e9 Carragelose \u00e0 Unither Pharmaceuticals Toutes les conditions n\u00e9cessaires \u00e0 la cl\u00f4ture de la transaction, y compris l&rsquo;approbation des actionnaires et la fin de la proc\u00e9dure de restructuration, ont \u00e9t\u00e9 remplies La cl\u00f4ture est assortie d\u2019un paiement initial de 5 millions d\u2019euros Marinomed et Unither [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":19653,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19,209],"tags":[],"class_list":["post-26676","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites","category-communique-de-presse"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Finalisation de la cession de l&#039;activit\u00e9 Carragelose | Unither<\/title>\n<meta name=\"description\" content=\"Finalisation de la cession de l&#039;activit\u00e9 Carragelose | Unither\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Finalisation de la cession de l&#039;activit\u00e9 Carragelose | Unither\" \/>\n<meta property=\"og:description\" content=\"Finalisation de la cession de l&#039;activit\u00e9 Carragelose | Unither\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/\" \/>\n<meta property=\"og:site_name\" content=\"Unither\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-19T09:55:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T15:57:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png\" \/>\n\t<meta property=\"og:image:width\" content=\"992\" \/>\n\t<meta property=\"og:image:height\" content=\"661\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@UnitherPharma\" \/>\n<meta name=\"twitter:site\" content=\"@UnitherPharma\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/person\/eb53be7b5e854190989b3a8783d0cc28\"},\"headline\":\"Finalisation de la cession de l&rsquo;activit\u00e9 Carragelose\",\"datePublished\":\"2025-02-19T09:55:35+00:00\",\"dateModified\":\"2026-03-30T15:57:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/\"},\"wordCount\":964,\"publisher\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png\",\"articleSection\":[\"Actualit\u00e9s\",\"Communiqu\u00e9 de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/\",\"url\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/\",\"name\":\"Finalisation de la cession de l'activit\u00e9 Carragelose | Unither\",\"isPartOf\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png\",\"datePublished\":\"2025-02-19T09:55:35+00:00\",\"dateModified\":\"2026-03-30T15:57:07+00:00\",\"description\":\"Finalisation de la cession de l'activit\u00e9 Carragelose | Unither\",\"breadcrumb\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#primaryimage\",\"url\":\"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png\",\"contentUrl\":\"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png\",\"width\":992,\"height\":661},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.unither-pharma.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Finalisation de la cession de l&rsquo;activit\u00e9 Carragelose\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#website\",\"url\":\"https:\/\/www.unither-pharma.com\/fr\/\",\"name\":\"Unither\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.unither-pharma.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#organization\",\"name\":\"Unither\",\"url\":\"https:\/\/www.unither-pharma.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png\",\"contentUrl\":\"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png\",\"width\":514,\"height\":252,\"caption\":\"Unither\"},\"image\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/UnitherPharma\",\"https:\/\/www.linkedin.com\/company\/unither-pharmaceuticals\/\",\"https:\/\/www.youtube.com\/channel\/UCHaTbYrnICFU1MiLwNsKjMA\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/person\/eb53be7b5e854190989b3a8783d0cc28\",\"name\":\"admin\",\"sameAs\":[\"https:\/\/www.unither-pharma.com\"],\"url\":\"https:\/\/www.unither-pharma.com\/fr\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Finalisation de la cession de l'activit\u00e9 Carragelose | Unither","description":"Finalisation de la cession de l'activit\u00e9 Carragelose | Unither","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/","og_locale":"fr_FR","og_type":"article","og_title":"Finalisation de la cession de l'activit\u00e9 Carragelose | Unither","og_description":"Finalisation de la cession de l'activit\u00e9 Carragelose | Unither","og_url":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/","og_site_name":"Unither","article_published_time":"2025-02-19T09:55:35+00:00","article_modified_time":"2026-03-30T15:57:07+00:00","og_image":[{"width":992,"height":661,"url":"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@UnitherPharma","twitter_site":"@UnitherPharma","twitter_misc":{"\u00c9crit par":"admin","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#article","isPartOf":{"@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/"},"author":{"name":"admin","@id":"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/person\/eb53be7b5e854190989b3a8783d0cc28"},"headline":"Finalisation de la cession de l&rsquo;activit\u00e9 Carragelose","datePublished":"2025-02-19T09:55:35+00:00","dateModified":"2026-03-30T15:57:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/"},"wordCount":964,"publisher":{"@id":"https:\/\/www.unither-pharma.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#primaryimage"},"thumbnailUrl":"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png","articleSection":["Actualit\u00e9s","Communiqu\u00e9 de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/","url":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/","name":"Finalisation de la cession de l'activit\u00e9 Carragelose | Unither","isPartOf":{"@id":"https:\/\/www.unither-pharma.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#primaryimage"},"image":{"@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#primaryimage"},"thumbnailUrl":"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png","datePublished":"2025-02-19T09:55:35+00:00","dateModified":"2026-03-30T15:57:07+00:00","description":"Finalisation de la cession de l'activit\u00e9 Carragelose | Unither","breadcrumb":{"@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#primaryimage","url":"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png","contentUrl":"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2024\/12\/csm_Design_ohne_Titel_8d19d6fbf8.png","width":992,"height":661},{"@type":"BreadcrumbList","@id":"https:\/\/www.unither-pharma.com\/fr\/finalisation-de-la-cession-de-lactivite-carragelose\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.unither-pharma.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Finalisation de la cession de l&rsquo;activit\u00e9 Carragelose"}]},{"@type":"WebSite","@id":"https:\/\/www.unither-pharma.com\/fr\/#website","url":"https:\/\/www.unither-pharma.com\/fr\/","name":"Unither","description":"","publisher":{"@id":"https:\/\/www.unither-pharma.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.unither-pharma.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.unither-pharma.com\/fr\/#organization","name":"Unither","url":"https:\/\/www.unither-pharma.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png","contentUrl":"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png","width":514,"height":252,"caption":"Unither"},"image":{"@id":"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/UnitherPharma","https:\/\/www.linkedin.com\/company\/unither-pharmaceuticals\/","https:\/\/www.youtube.com\/channel\/UCHaTbYrnICFU1MiLwNsKjMA"]},{"@type":"Person","@id":"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/person\/eb53be7b5e854190989b3a8783d0cc28","name":"admin","sameAs":["https:\/\/www.unither-pharma.com"],"url":"https:\/\/www.unither-pharma.com\/fr\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/posts\/26676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/comments?post=26676"}],"version-history":[{"count":1,"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/posts\/26676\/revisions"}],"predecessor-version":[{"id":26677,"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/posts\/26676\/revisions\/26677"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/media\/19653"}],"wp:attachment":[{"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/media?parent=26676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/categories?post=26676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/tags?post=26676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}